Abdelkbir ERROUGUI

Prof. Dr. Abdelkbir ERROUGUI

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MKMeriem Khedraoui
Meriem Khedraoui
OAOussama ABCHIR
Oussama ABCHIR
HNHASSAN NOUR
HASSAN NOUR
Imane YamariImane Yamari
Imane Yamari
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
SCSamir Chtita
Samir Chtita
Acetylcholinesterase (AChE) is one of the main drug targets for treating Alzheimer’s disease. This current study relies on multiple molecular modeling approaches to develop new potent inhibitors of AChE. We explored a 2D QSAR study using the statistical method of multiple linear regression based on a set of substituted 5-phenyl-1,3,4-oxadiazole and N-benzylpiperidine analogs, which were recently synthesized and proved their inhibitory activities against acetylcholinesterase (AChE). The molecular descriptors, polar surface area, dipole moment, and molecular weight are the key structural properties governing AChE inhibition activity. The MLR model was selected based on its statistical parameters: R2 = 0.701, R2test = 0.76, Q2CV = 0.638, and RMSE = 0.336, demonstrating its predictive reliability. Randomization tests, VIF tests, and applicability domain tests were adopted to verify the model’s robustness. As a result, 11 new molecules were designed with higher anti-Alzheimer’s activities than the model molecule. We demonstrated their improved pharmacokinetic properties through an in silico ADMET study. A molecular docking study was conducted to explore their AChE inhibition mechanisms and binding affinities in the active site. The binding scores of compounds M1, M2, and M6 were (−12.6 kcal/mol), (−13 kcal/mol), and (−12.4 kcal/mol), respectively, which are higher than the standard inhibitor Donepezil with a binding score of (−10.8 kcal/mol). Molecular dynamics simulations over 100 ns were used to validate the molecular docking results, indicating that compounds M1 and M2 remain stable in the active site, confirming their potential as promising anti-AChE inhibitors.

19 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
OAOussama ABCHIR
Oussama ABCHIR
MKMeriem Khedraoui
Meriem Khedraoui
HNHassan Nour
Hassan Nour
Imane YamariImane Yamari
Imane Yamari
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
SCSamir Chtita
Samir Chtita
In response to the increasing prevalence of diabetes mellitus and the limitations associated with the current treatments, there is a growing need to develop novel medications for this disease. This study is focused on creating new compounds that exhibit a strong inhibition of alpha-glucosidase, which is a pivotal enzyme in diabetes control. A set of 33 triazole derivatives underwent an extensive QSAR analysis, aiming to identify the key factors influencing their inhibitory activity against α-glucosidase. Using the multiple linear regression (MLR) model, seven promising compounds were designed as potential drugs. Molecular docking and dynamics simulations were employed to shed light on the mode of interaction between the ligands and the target, and the stability of the obtained complexes. Furthermore, the pharmacokinetic properties of the designed compounds were assessed to predict their behavior in the human body. The binding free energy was also calculated using MMGBSA method and revealed favorable thermodynamic properties. The results highlighted three novel compounds with high biological activity, strong binding affinity to the target enzyme, and suitability for oral administration. These results offer interesting prospects for the development of effective and well-tolerated medications against diabetes mellitus.

13 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ABAmal Bouribab
Amal Bouribab
EKEl Mehdi Karim
El Mehdi Karim
MKMeriem Khedraoui
Meriem Khedraoui
OAOussama ABCHIR
Oussama ABCHIR
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
SCSamir Chtita
Samir Chtita
Background: Angiogenesis is a crucial process in the growth and proliferation of cancer, enabling tumor growth through the formation of new vasculature and the supply of nutrients and oxygen to growing malignant cells. This disease-promoting process can be targeted through the inhibition of tyrosine kinase enzymes. Objectives: The objective of this study is to evaluate the anticancer potential of various Moroccan plants from different regions. While these plants have a rich history of traditional medicinal use, they have not been extensively investigated as anticancer therapies. Methods: This study employed a multifaceted approach to evaluate the anticancer potential of various Moroccan plants. Receptor–ligand docking and virtual screening were used to assess the binding affinity of phytocompounds to the EGFR and VEGFR2 receptors. Additionally, predictive pharmacokinetic analyses were conducted to evaluate the ADMET properties of the selected compounds, followed by molecular dynamics simulations to analyze the stability of the receptor–ligand complexes. Results: In our research, we identified three notable active compounds—catechin, 4-O-glucoside ferulic acid, and 3-glucoside resveratrol—in the Moroccan plant Ajuga iva L. These findings suggest that Ajuga iva L. may possess significant potential for cancer inhibition. Conclusions: This research highlights the potential of the Moroccan plant Ajuga iva L. as a source of active compounds with significant anticancer properties. Further investigation is essential to validate these findings and explore new therapeutic avenues based on these traditional resources.

22 November 2022 in Journal of Solution Chemistry
Verified
Journal Article
Closed access
PDF file
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI
ALAyoub Lahmidi
Ayoub Lahmidi
SCSamir Chtita
Samir Chtita
MKMhammed El Kouali
Mhammed El Kouali
MTMohammed Talbi
Mohammed Talbi

4 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Imane YamariImane Yamari
Imane Yamari
OAOussama ABCHIR
Oussama ABCHIR
HNHASSAN NOUR
HASSAN NOUR
MKMeriem Khedraoui
Meriem Khedraoui
BRBouchra Rossafi
Bouchra Rossafi
SCSamir Chtita
Samir Chtita
Candida albicans and Aspergillus fumigatus are recognized as significant fungal pathogens, responsible for various human infections. The rapid emergence of drug-resistant strains among these fungi requires the identification and development of innovative antifungal therapies. We undertook a comprehensive screening of 297 naturally occurring compounds to address this challenge. Using computational docking techniques, we systematically analyzed the binding affinity of each compound to key proteins from Candida albicans (PDB ID: 1EAG) and Aspergillus fumigatus (PDB ID: 3DJE). This rigorous in silico examination aimed to unveil compounds that could potentially inhibit the activity of these fungal infections. This was followed by an ADMET analysis of the top-ranked compound, providing valuable insights into the pharmacokinetic properties and potential toxicological profiles. To further validate our findings, the molecular reactivity and stability were computed using the DFT calculation and molecular dynamics simulation, providing a deeper understanding of the stability and behavior of the top-ranking compounds in a biological environment. The outcomes of our study identified a subset of natural compounds that, based on our analysis, demonstrate notable potential as antifungal candidates. With further experimental validation, these compounds could pave the way for new therapeutic strategies against drug-resistant fungal pathogens.

30 November 2023 in Chemical Physics Impact
Verified
Journal Article
Open access
ALAyoub Lahmidi
Ayoub Lahmidi
SRSanaa Rabii
Sanaa Rabii
SCSamir Chtita
Samir Chtita
MKMhammed El Kouali
Mhammed El Kouali
MTMohammed Talbi
Mohammed Talbi
AEAbdelkbir ERROUGUI
Abdelkbir ERROUGUI